Clinical Trials Browser

INDUSTRY × Leukemia, Hairy Cell × immunotoxin HA22 × Clear all

NCT03501615 2020-06-29

MOXE

Approved for marketing

Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell

NCT01829711 2020-04-08

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

Phase 3 Completed

80 enrolled 32 charts 1 FDA

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT00586924 2019-04-02

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

Phase 1 Completed

49 enrolled 40 charts

Other hematologic neoplasm

Leukemia, Hairy Cell